Once daily low-dose aspirin reduces urinary thromboxane B2 effectively even at 12-24 hours from dosing in the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial
Main Authors: | Aung, T, Buck, GAN, Parish, S, Bowman, L, Armitage, J |
---|---|
Other Authors: | The ASCEND Collaborative Group |
Format: | Conference item |
Language: | English |
Published: |
Oxford University Press
2017
|
Similar Items
-
Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
by: Parish, S, et al.
Published: (2023) -
Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
by: Sarah Parish, et al.
Published: (2023-03-01) -
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial
by: Petrucci, G, et al.
Published: (2024) -
ASCEND-Eye: effects of aspirin on diabetic retinopathy
by: Sammons, E, et al.
Published: (2024) -
Thromboxane metabolite excretion is associated with serious vascular events in diabetes mellitus: a sub-study of the ASCEND trial
by: Rocca, B, et al.
Published: (2020)